Chapter 11: The Aetiology and Genetics of Haematological Neoplasia

The Aetiology and Genetics of Haematological Neoplasia malignancies are fundamentally clonal, meaning they originate from a single progenitor cell in the bone marrow or lymphoid tissues that has acquired significant genetic alterations. While these cancers account for roughly seven percent of all malignant diseases, their distribution varies significantly across different global populations, such as the high prevalence of certain leukaemias in Western nations compared to the Far East. The development of these conditions is driven by a combination of inherited predispositions—such as those seen in Down syndrome, Fanconi anaemia, or specific germline mutations—and various environmental triggers. These triggers include chronic exposure to industrial toxins like benzene, specific chemotherapy drugs like DNA alkylating agents, ionising radiation, and certain viral or bacterial infections like Epstein-Barr virus, HIV, or Helicobacter pylori. On a molecular level, the transition to a malignant state involves a delicate imbalance between activated oncogenes, which promote excessive cell growth and survival, and inactivated tumour-suppressor genes, most notably TP53, which normally regulate cell cycle integrity and DNA damage responses. Modern haematology classifies these diseases through the identification of specific driver mutations, such as those affecting tyrosine kinases like JAK2 or FLT3, and structural chromosomal changes including translocations, deletions, and inversions. The progression of these diseases often follows complex evolutionary patterns, where multiple subclones compete or emerge during treatment, leading to clinical relapses even after successful initial therapy. Furthermore, the discovery of clonal haematopoiesis in healthy, often elderly, individuals suggests that some genetic mutations may exist long before clinical disease becomes apparent. Advancements in diagnostic technology, such as flow cytometry, fluorescence in situ hybridization (FISH), and next-generation sequencing, now allow for precise identification of these abnormalities by analyzing cell surfaces and DNA sequences. These tools are indispensable for modern clinical management, enabling doctors to establish accurate diagnoses, tailor therapeutic protocols to an individual's specific genetic profile, and monitor for minimal residual disease with extreme sensitivity. By understanding the epigenetic modifications, such as DNA methylation, and chromosomal instabilities that define these neoplasms, medical professionals can better predict patient outcomes and refine the use of targeted therapies to improve survival rates.